Bispecific antibody molecule
CA 2505342 C · Owner: Jung, Gundram · Inventors: Jung, Gundram
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
A first bispecific antibody molecule comprises at least one binding site with a variable domain on a light chain (V<SB>L</SB>) and a variable domain for the T-cell receptor CD-28, linked thereto on a heavy chain (Vh). The antibody molecule further comprises at least one binding site with a variable domain on a heavy chain (V<SB>H</SB>) and a variable domain for a tumour antigen linked , thereto on a light chain (V<SB>L</SB>). The variable domains on the heavy chains for both specificities are connected to each other by means of a peptide linker. A second bispecific antibody molecule is bivalent for CD-28 and at least monovalent for the tumour antigen.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed November 9, 2002 and granted January 29, 2013. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended November 9, 2022.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by November 9, 2024.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.